In recent years, the world has witnessed in the emergence of several infectious diseases, with notable examples being coronavirus disease 2019 (COVID-19), avian influenza, and Mpox, which continue to present serious and persistent threats to global public health. The rapid spread and devastating impact of these diseases underscore the urgent need for effective combat strategies. One promising area of research in the field of antiviral drug development is the exploration of multi-specific antibodies. These have attracted significant attention owing to their diverse benefits compared to monoclonal antibodies. Multi-specific antibodies exhibit a more versatile function, possess a stronger binding affinity for viral targets, demonstrate enhanced antiviral activity, and show reduced susceptibility to viral escape mechanisms. These characteristics make them promising candidates for the development of novel antiviral therapies against a range of emerging infectious diseases. This review examines the current research progress surrounding multi-specific antibodies in the context of combating SARS-CoV-2, influenza virus, and other newly emerging infectious viruses. It offers insights into the potential applications and future prospects of multi-specific antibodies, with the aim to contribute to the ongoing efforts to address the global health challenges posed by infectious diseases.